Why FETO exists
Severe congenital diaphragmatic hernia kills infants through pulmonary hypoplasia, not the anatomic defect itself 0:46. Fetoscopic endoluminal tracheal occlusion—FETO—addresses this by placing a detachable balloon in the fetal trachea 0:46. The occluded airway traps lung fluid, distends the developing lungs, and drives alveolar growth 0:46. The balloon is removed before delivery 0:46. Randomized trials have shown FETO improves survival in severe left-sided CDH 0:46. The question this multicentre cohort study addresses is what happens to the trachea itself.
The core problem
A balloon sitting in the fetal trachea for weeks exerts radial pressure on cartilage that is still forming. The concern has been whether this mechanical insult produces lasting airway pathology—specifically tracheomalacia, in which the tracheal wall lacks the rigidity to stay patent during the respiratory cycle, or tracheomegaly, an abnormally wide trachea that may predispose to ineffective clearance and recurrent infection 0:24 0:33. Both conditions can complicate extubation, prolong NICU stays, and require ongoing pulmonary management. For a procedure that saves lives by growing lungs, creating a dysfunctional airway would be a bitter trade.
What this study found
The investigators reviewed outcomes in infants with CDH managed with or without FETO across multiple centres 0:24. Three findings define the tracheal phenotype after balloon occlusion.
First, tracheomalacia was more common in the FETO group—5% higher prevalence overall, with 4% more diagnosed cases 0:24. This is not a subtle signal. However, the natural history matters as much as the incidence: symptoms typically resolved within 55 months 0:29. The study does not detail what "resolution" meant clinically—whether these children required intervening airway procedures, prolonged positive pressure, or simply outgrew the problem—but the implication is that FETO-associated tracheomalacia behaves as a transient rather than permanent condition 0:46.
Second, FETO-treated infants had wider tracheas, approximately 31% larger in diameter than controls 0:33. This is tracheomegaly by definition, though the study does not report whether the increased caliber translated into clinical airway dysfunction. A dilated trachea can be mechanically disadvantageous—cough becomes less effective, secretions pool—but diameter alone does not determine pathology. The question is whether this anatomic change persists and whether it matters beyond infancy.
Third, 37% of FETO cases retained metallic components from the balloon after removal 0:33. This is a startling figure. The balloon is designed to be retrieved intact, yet more than one in three infants were left with foreign material in the airway 0:33. Remarkably, no significant complications were attributed to these retained fragments 0:33. Whether this reflects true benignity or incomplete follow-up is unclear, but it raises the question of whether routine bronchoscopy after FETO should be considered to document clearance.
What remains uncertain
The study does not stratify tracheomalacia severity 0:24. Mild collapse on bronchoscopy is common and often asymptomatic; severe tracheomalacia requiring aortopexy or stenting is a different problem entirely. Without severity grading, it is difficult to counsel families on what the 5% increased risk actually means in terms of morbidity.
The mechanism behind the increased tracheal diameter is also unexplained 0:33. Is this simply mechanical dilation from the balloon, or does the occlusion alter tracheal growth signaling in a way that persists after the balloon is removed? If the latter, the effect might be durable; if the former, one would expect gradual normalization, though the study does not report long-term diameter measurements.
Finally, the cohort design cannot separate the effects of FETO from the effects of severe CDH itself. Infants sick enough to warrant fetal intervention may have baseline airway differences. The comparison group—CDH managed expectantly—likely includes less severe cases, which introduces selection bias. A true assessment of FETO's isolated tracheal impact would require randomized data with protocolized airway imaging, which this study does not provide.
When to think about this
For neonatologists and pediatric intensivists managing post-FETO infants, this study suggests a higher index of suspicion for tracheomalacia during the extubation process 0:24 0:29. If an infant fails extubation without clear parenchymal explanation, airway imaging is warranted. For pediatric surgeons counseling families considering FETO, the data support framing tracheomalacia as a recognized, generally self-limited consequence rather than a rare complication 0:24 0:29 0:46. The retained balloon fragments are harder to contextualize—current evidence suggests they are inert, but the lack of reported complications may reflect short follow-up rather than true safety 0:33 0:33.
For pulmonologists following these children long-term, the question is whether the increase in tracheal diameter has implications for airway clearance, infection risk, or exercise tolerance as they grow 0:33. The study does not answer this, which means the answer is: we do not yet know.
Takeaways from this story
- FETO increases tracheomalacia risk by 5%, but symptoms typically resolve within 55 months in most cases.
- Post-FETO tracheas are approximately 31% wider than controls; clinical significance of this tracheomegaly is unclear.
- Over one-third of FETO cases retain metallic balloon fragments, though no complications were reported in this cohort.
- FETO remains effective for promoting lung growth in severe CDH despite these tracheal effects.
